Baxter to buy Gambro? Analysts give cautious thumbs up
This article was originally published in Clinica
Executive Summary
Unconfirmed media reports about Baxter mulling a $4 billion acquisition of Swedish kidney dialysis firm Gambro have driven shares in the Deerfield, Illinois company to their highest level in over four years. If true, the transaction would be the largest in Baxter's history and significantly expand its existing dialysis business.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.